More News! Results from AB Science and Newron in MS & Schizophrenia

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Best dog photo

  • Selvita licensed its dual PIM/FLT3 inhibitor for acute myeloid leukemia pateints that’s currently in Phase I/II to Berlin-Chemie Menarini
  • GSK and Warp Drive Bio have partnered up to ‘drug the undraggable’ disease-associated proteins.

Andrei Kobylko

  • Following the FDA approval of Xadago last week, Newron has brought more good news form its schizophrenia candidate
  • AB Science‘s MS antibody has passed the non futility test in Phase III
  • Transgene has described its new generation of armed oncolytic viruses

Kuznetsov Alexey

  • Gilead is taking heat from various European humanitarian organisations over its Hep C blockbuster
  • FierceBiotech answered all (well, most of) our questions about Brexit this week
  • Novo Nordisk has resubmitted its NDA for fast-acting insulin aspart in the US — here’s more on its successor

Images from Andrei Kobylko, Best dog photo, colin rovers varndell, Kuznetsov Alexey /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.